Vaia Stavropoulou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Vaia Stavropoulou has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Alexandre Fagnan
Gustave Roussy cancer center, Université Paris Diderot, Université Paris-Sud, OPALE Carnot Institute, PEDIAC consortium
2 shared publications - Antoine Hendrik Felix Marie Peters
Friedrich Miescher Institute for Biomedical Research, Fabrikstrasse 24, 4056 Basel, Switzerland
2 shared publications - Arnaud Petit
Hopital Armand Trousseau, APHP.Sorbonne Université, Paris, France
2 shared publications - Bastien Job
Gustave Roussy Institute of Oncology, Villejuif, France
2 shared publications - Berthold Göttgens
Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK
2 shared publications - Camille Lobry
INSERM UMR 1342, Institut de Recherche Saint-Louis, Paris, France
2 shared publications
Latest Publications
- Top Cited PapersOpen Access
- 1 May 2026
- Published by Springer Nature in Nature Cancer
- Vol. 7 (5) , 810-822
Tumor-localized CD40 agonism with MP0317, a FAP x CD40 DARPin, reprograms the tumor microenvironment in patients with advanced solid tumors: an open-label, nonrandomized, dose-escalation phase 1 study
This phase 1, open-label, nonrandomized, dose-escalation study evaluated MP0317 (FAP x CD40 DARPin) in adults with advanced solid tumors. Forty-six patients across nine cohorts received MP0317 at doses ranging from 0.03 to 10 mg kg −1 intravenously weekly or every 3 weeks. The primary outcome measure was safety; secondary and exploratory outcome measures included antitumor activity, pharmacokinetics and pharmacodynamics. Most treatment-related adverse events were of grades 1 and 2 (95%); a maximum tolerated dose was not reached. One patient achieved an unconfirmed partial response and 14 patients had stable disease. MP0317 serum pharmacokinetics confirmed extended half-life properties; terminal half-life estimates increased with dose and ranged from 21.8 to 120 h. Paired tumor biopsies confirmed colocalization of MP0317 with fibroblast activation protein and CD40. Activation of the CD40 pathway in the tumor microenvironment was shown by increased infiltration of antigen-presenting, plasma and follicular helper T cells, dendritic cell maturation, interferon-γ signaling and circulating immune markers. Collectively, these data confirm a favorable safety profile for MP0317 and support further clinical evaluation in combination with complementary immunotherapies. ClinicalTrials.gov registration: NCT05098405 .
- 1 May 2026
- Published by Springer Nature in Nature Cancer
- Vol. 7 (5) , 810-822
Top Cited PapersOpen AccessTumor-localized CD40 agonism with MP0317, a FAP x CD40 DARPin, reprograms the tumor microenvironment in patients with advanced solid tumors: an open-label, nonrandomized, dose-escalation phase 1 study
This phase 1, open-label, nonrandomized, dose-escalation study evaluated MP0317 (FAP x CD40 DARPin) in adults with advanced solid tumors. Forty-six patients across nine cohorts received MP0317 at doses ranging from 0.03 to 10 mg kg −1 intravenously weekly or every 3 weeks. The primary outcome measure was safety; secondary and exploratory outcome measures included antitumor activity, pharmacokinetics and pharmacodynamics. Most treatment-related adverse events were of grades 1 and 2 (95%); a maximum tolerated dose was not reached. One patient achieved an unconfirmed partial response and 14 patients had stable disease. MP0317 serum pharmacokinetics confirmed extended half-life properties; terminal half-life estimates increased with dose and ranged from 21.8 to 120 h. Paired tumor biopsies confirmed colocalization of MP0317 with fibroblast activation protein and CD40. Activation of the CD40 pathway in the tumor microenvironment was shown by increased infiltration of antigen-presenting, plasma and follicular helper T cells, dendritic cell maturation, interferon-γ signaling and circulating immune markers. Collectively, these data confirm a favorable safety profile for MP0317 and support further clinical evaluation in combination with complementary immunotherapies. ClinicalTrials.gov registration: NCT05098405 .
- Open Access
A phase 1b/2 study evaluating efficacy and safety of MP0250, a designed ankyrin repeat protein (DARPin) simultaneously targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), in combination with bortezomib and dexamethasone, in patients with relapsed or refractory multiple myeloma
MP0250 is a designed ankyrin repeat protein that specifically inhibits both vascular endothelial growth factor A (VEGF‐A) and hepatocyte growth factor (HGF), aiming at potentiating cancer therapy by disrupting the tumour microenvironment. Encouraging results from a phase 1 trial of MP0250 in patients with solid tumours prompted further investigation in multiple myeloma (MM) as both MP0250 targets are reported to be drivers of MM pathogenesis.In this open‐label, single‐arm phase 1b/2 study (NCT03136653) in patients with proteasome inhibitor‐ and/or immunomodulatory drug‐relapsed or refractory MM, MP0250 was administered every 3 weeks with standard bortezomib/dexamethasone regimen.Thirty‐three patients received at least one dose of MP0250. The most frequent treatment‐related adverse events were arterial hypertension (58.1%), thrombocytopenia (32.3%), proteinuria (29.0%) and peripheral oedema (19.4%). Of the 28 patients evaluable for response (median age: 60 [range 44–75]), nine achieved at least partial response, corresponding to an overall response rate of 32.1% (95% confidence interval [CI]: 17.9%, 50.7%), with a median duration of response of 8 months (95% CI 5–NR). An additional three patients achieved minimal response and nine stable diseases as the best overall response. Overall median progression‐free survival was 4.2 months (95% CI 1.9–7.1).These findings are in line with the results of recent trials testing new agents on comparable patient cohorts and provide initial evidence of clinical benefit for patients with refractory/relapsed MM treated with MP0250 in combination with bortezomib/dexamethasone. Further clinical evaluation in the emerging MM treatment landscape would be required to confirm the clinical potential of MP0250.
Open AccessA phase 1b/2 study evaluating efficacy and safety of MP0250, a designed ankyrin repeat protein (DARPin) simultaneously targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), in combination with bortezomib and dexamethasone, in patients with relapsed or refractory multiple myeloma
MP0250 is a designed ankyrin repeat protein that specifically inhibits both vascular endothelial growth factor A (VEGF‐A) and hepatocyte growth factor (HGF), aiming at potentiating cancer therapy by disrupting the tumour microenvironment. Encouraging results from a phase 1 trial of MP0250 in patients with solid tumours prompted further investigation in multiple myeloma (MM) as both MP0250 targets are reported to be drivers of MM pathogenesis.In this open‐label, single‐arm phase 1b/2 study (NCT03136653) in patients with proteasome inhibitor‐ and/or immunomodulatory drug‐relapsed or refractory MM, MP0250 was administered every 3 weeks with standard bortezomib/dexamethasone regimen.Thirty‐three patients received at least one dose of MP0250. The most frequent treatment‐related adverse events were arterial hypertension (58.1%), thrombocytopenia (32.3%), proteinuria (29.0%) and peripheral oedema (19.4%). Of the 28 patients evaluable for response (median age: 60 [range 44–75]), nine achieved at least partial response, corresponding to an overall response rate of 32.1% (95% confidence interval [CI]: 17.9%, 50.7%), with a median duration of response of 8 months (95% CI 5–NR). An additional three patients achieved minimal response and nine stable diseases as the best overall response. Overall median progression‐free survival was 4.2 months (95% CI 1.9–7.1).These findings are in line with the results of recent trials testing new agents on comparable patient cohorts and provide initial evidence of clinical benefit for patients with refractory/relapsed MM treated with MP0250 in combination with bortezomib/dexamethasone. Further clinical evaluation in the emerging MM treatment landscape would be required to confirm the clinical potential of MP0250.